ZA913865B - Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases - Google Patents

Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases

Info

Publication number
ZA913865B
ZA913865B ZA913865A ZA913865A ZA913865B ZA 913865 B ZA913865 B ZA 913865B ZA 913865 A ZA913865 A ZA 913865A ZA 913865 A ZA913865 A ZA 913865A ZA 913865 B ZA913865 B ZA 913865B
Authority
ZA
South Africa
Prior art keywords
naphthylethyl
tetrahydropyridine
trifluoromethylphenyl
cerebral
medicament
Prior art date
Application number
ZA913865A
Other languages
English (en)
Inventor
Francois Xavier Goude
Xavier Goude Francois
Jacqueline Fournier
Fournier Jacqueline
Umberto Guzzi
Guzzi Umberto
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA913865B publication Critical patent/ZA913865B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
ZA913865A 1990-05-22 1991-05-22 Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases ZA913865B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (1)

Publication Number Publication Date
ZA913865B true ZA913865B (en) 1992-02-26

Family

ID=9396855

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA913865A ZA913865B (en) 1990-05-22 1991-05-22 Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases

Country Status (17)

Country Link
US (3) US5229389A (da)
EP (2) EP0458696B1 (da)
JP (2) JP2618115B2 (da)
KR (1) KR0181330B1 (da)
AT (2) ATE207747T1 (da)
BR (1) BR9105015A (da)
CA (2) CA2365832C (da)
CY (1) CY2283B1 (da)
DE (2) DE69115989T2 (da)
DK (2) DK0458696T3 (da)
FR (1) FR2662355B1 (da)
HK (1) HK1001471A1 (da)
HU (1) HU208922B (da)
IE (1) IE911707A1 (da)
IL (3) IL98175A (da)
TW (1) TW216771B (da)
ZA (1) ZA913865B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
KR100472793B1 (ko) * 1995-10-26 2005-06-16 사노피-신델라보 근위축성측삭경화증치료용약제를제조하기위한1-(2-나프트-2-일에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6-테트라히드로피리딘의용도
ATE346303T1 (de) * 1996-03-29 2006-12-15 Univ Boston Mit alzheimer krankheit verknüpften verfahren zur diagnose, zur herstellung von medikamenten und zum screenen von substanzen sowie aus beta- amyloid abgeleiteten peptiden
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
JP2001511141A (ja) * 1997-02-03 2001-08-07 サノフィ−サンテラボ １−［４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリド−１−イル］−２−（６，７−ジメトキシナフト−２−イル）エタンの、脳障害および神経障害を治療する目的の薬剤を調製するための使用
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
IE911707A1 (en) 1991-12-04
KR0181330B1 (ko) 1999-03-20
IL112167A (en) 1996-01-31
JPH04226917A (ja) 1992-08-17
EP0458696A2 (fr) 1991-11-27
DE69115989D1 (de) 1996-02-15
CA2365832C (en) 2007-08-07
IL98175A (en) 1996-01-19
DK0655247T3 (da) 2002-02-18
AU636488B2 (en) 1993-04-29
DE69132797T2 (de) 2002-05-29
CA2365832A1 (en) 1991-11-23
ATE207747T1 (de) 2001-11-15
HK1001471A1 (en) 1998-06-19
JP2954029B2 (ja) 1999-09-27
US5270320A (en) 1993-12-14
CA2042974C (en) 2002-09-17
US5229389A (en) 1993-07-20
JPH09132535A (ja) 1997-05-20
FR2662355A1 (fr) 1991-11-29
DE69132797D1 (de) 2001-12-06
EP0458696B1 (fr) 1996-01-03
KR910019617A (ko) 1991-12-19
HU911729D0 (en) 1991-12-30
DK0458696T3 (da) 1996-05-20
IE20011078A1 (en) 2002-03-20
TW216771B (da) 1993-12-01
FR2662355B1 (fr) 1994-11-10
DE69115989T2 (de) 1996-08-22
CY2283B1 (en) 2003-07-04
BR9105015A (pt) 1993-05-25
JP2618115B2 (ja) 1997-06-11
EP0458696A3 (en) 1992-03-18
AU7713391A (en) 1991-11-28
IL98175A0 (en) 1992-06-21
EP0655247B1 (fr) 2001-10-31
CA2042974A1 (en) 1991-11-22
ATE132369T1 (de) 1996-01-15
HUT59824A (en) 1992-07-28
HU208922B (en) 1994-02-28
EP0655247A1 (fr) 1995-05-31
IL112167A0 (en) 1995-03-15
US5468753A (en) 1995-11-21

Similar Documents

Publication Publication Date Title
ZA913865B (en) Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases
DE288447T1 (de) Ein verfahren und eine zusammensetzung fuer die behandlung neurologischer krankheiten wie migraene, durch beeinflussung der nervenzellen.
DE3886768D1 (de) Vorrichtung zum herstellen von kunststoff-formteilen und verwendung der vorrichtung.
DE69435246D1 (de) Verwendung von Docosahexaensäure zur Herstellung eines Arzneimittels zur Behandlung der senilen Demenz und Alzheimer-Erkrankung
DE69534002D1 (de) Verwendung von Phosphatidylserinen zur Herstellung eines Arzneimittels zur Verbesserung der Gehirntätigkeit
EP0616032A3 (en) Preventive or therapeutic agents for Alzheimer's disease, a seven-test method, and human tau protein kinase.
DE68912419T2 (de) Verwendung von Uridin zur Behandlung nervöser Störungen.
DE58907944D1 (de) Verfahren und Vorrichtung zum Herstellen von hochverdichteten zylindrischen Presslingen aus losem Halmgut.
DE68925004D1 (de) Verwendung von 2,3,4,5-Tetrahydro-1H-3-Benzazepinen bei der Behandlung von neurologischen Störungen.
ATE137745T1 (de) Arylpyrrol enthaltende insekticidale, acaricidale und nematicidale mittel sowie verfahren zu ihrer herstellung
ATE143809T1 (de) Placentaextrakt und verfahren zu seiner herstellung
DE68905837D1 (de) 2-(alkyl-cyclohexyl)-1-propanol, verfahren zu dessen herstellung und ihn enthaltende riechstoffzusammensetzung.
HU901636D0 (en) Process for producing new benzothio-pyranyl-amines and pharmaceutical preparatives containing them as active substance
DE3889043T2 (de) N-(substituiertes Alkyliden)-1,2,3,4-tetrahydro-9-acridinamine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE58905617D1 (de) Verfahren zur Überwachung und/oder Regelung eines Spritzgiessprozesses.
ATA271985A (de) Verfahren zur herstellung von n-alkyl/en/-n-/o,o- disubstituierten thiophosphoryl/-n'n'disubstituierten-glycinamiden und diese verbindungen enthaltende akarizide, insektizide und fungizide mittel
DE3870912D1 (de) 4,4'-(perfluorisopropyliden)dicyclohexanol, dessen abkoemmling und verfahren zur herstellung davon.
EP0230863A3 (de) Oxadiazinone
DE59002586D1 (de) Verfahren und vorrichtung zur individuellen herstellung eines zahnersatzteils.
DE3863665D1 (de) 2-(benzhydrylsulfonyl) acetamid, verfahren zu dessen herstellung und dessen verwendung in der therapie.